| Page 1844 | Kisaco Research
 

Dr Magda Barbu

Senior Director, Synthetic Biology
C3J therapeutics

Dr. Magda Barbu, Senior Director of Synthetic Biology, leads engineering efforts for C3J’s pipeline of phage therapeutics programs.  Dr. Barbu is an established scientist with over 15 years of experience working with lytic and lysogenic phage in both industry and academia.  Magda combines her deep expertise in molecular biology, phage biology, bacterial pathogenesis and antimicrobial drug development, to set strategy and deliver key preclinical data essential for advancing the synthetic phage programs from bench to clinic. 

 

Dr Magda Barbu

Senior Director, Synthetic Biology
C3J therapeutics

Dr Magda Barbu

Senior Director, Synthetic Biology
C3J therapeutics

Dr. Magda Barbu, Senior Director of Synthetic Biology, leads engineering efforts for C3J’s pipeline of phage therapeutics programs.  Dr. Barbu is an established scientist with over 15 years of experience working with lytic and lysogenic phage in both industry and academia.  Magda combines her deep expertise in molecular biology, phage biology, bacterial pathogenesis and antimicrobial drug development, to set strategy and deliver key preclinical data essential for advancing the synthetic phage programs from bench to clinic. 

 

Dr. Barbu earned her Ph.D. in Microbiology/Molecular Genetics and Biochemistry from the University of Texas Health Science Center at Houston.  Magda completed her postdoctoral training at the MD Anderson Cancer Center, which included identifying druggable targets for cancer and other diseases using in vivo phage display.  She then worked at Synthetic Genomics, Inc. heading up development of the phage engineering platform and related assets, that were subsequently acquired by C3J Therapeutics. Magda has authored 18 peer-reviewed publications, presented worldwide as an invited speaker and received private and priority government grants for her research in antimicrobial therapeutics and synthetic biology.  She has several patents pending.

 

Anna Prokůpková

Policy & Project Officer
European Cancer Leagues

Anna Prokůpková

Policy & Project Officer
European Cancer Leagues

Anna Prokůpková

Policy & Project Officer
European Cancer Leagues
 

Anna Prokůpková

Policy & Project Officer
European Cancer Leagues

Anna Prokůpková

Policy & Project Officer
European Cancer Leagues

Anna Prokůpková

Policy & Project Officer
European Cancer Leagues
 

Fabio Fachin

Head, Cell Therapy Engineering & Automation
Takeda

Fabio Fachin

Head, Cell Therapy Engineering & Automation
Takeda

Fabio Fachin

Head, Cell Therapy Engineering & Automation
Takeda
 

Tatiana Golovina, PhD

Fellow, Cell & Gene Therapy, Process Development
Novartis Pharmaceuticals Corporation

Tatiana Golovina, PhD

Fellow, Cell & Gene Therapy, Process Development
Novartis Pharmaceuticals Corporation

Tatiana Golovina, PhD

Fellow, Cell & Gene Therapy, Process Development
Novartis Pharmaceuticals Corporation
 

Peggy Sotiropoulou

Head of R&D
Celyad Oncology

Peggy Sotiropoulou

Head of R&D
Celyad Oncology

Peggy Sotiropoulou

Head of R&D
Celyad Oncology
 

Matthew Tebeau

Chief Operating Officer
Proteon Pharmaceuticals SA

Matthew Tebeau

Chief Operating Officer
Proteon Pharmaceuticals SA

Matthew Tebeau

Chief Operating Officer
Proteon Pharmaceuticals SA
 

Ronie Schmelz

Tucker Ellis LLP

Ronie Schmelz

Tucker Ellis LLP

Ronie Schmelz

Tucker Ellis LLP